advertisement
Abstract #18384 Published in IGR 3-3
New medical treatment in glaucoma: new strategies?
Renard JP; May F; Rigal-Sastourne JC; Maurin JFJournal Français d'Ophtalmologie 2001; 24: 1095-1099
Several new classes of ocular hypotonia medications have recently become available. These include topical treatments carbonic anhydrase inhibitors, alpha-2 agonists, prostaglandin analogues, and a fixed combination of beta-blockers and carbonic anhydrase inhibitors. Being equal or superior in efficacy to beta-blockers, these new treatments must be reconsidered as first-line therapy in glaucoma. The long-term safety profile of antiglaucomatous drugs plays an important role in the new trends in medical treatment. These data, which will become better known and detailed over time by means of clinical experience, are changing our habits and advancing therapeutic strategies for more effective treatment, better suited to the individual, thus allowing the best quality of life possible. LA: French
Dr J.-P. Renard, Hôpital du Val-de-Grace, 74 Boulevard du Port-Royal, 75005 Paris, France
Classification:
11.1 General management, indication (Part of: 11 Medical treatment)
